Functional and systems biology approaches to Huntington's disease

Briefings in Functional Genomics

Volumn 10, Issue 3, 2011, Pages 109-114

  González Couto, Eduardo ^a  

^a Integromics SL   (Spain)

Author keywords

Bioinformatics; HD; Interactomics; Pathways; Proteomics; Transcriptomics

Indexed keywords

CHAPERONE; HUNTINGTIN; SMALL INTERFERING RNA;

ARTICLE; CAENORHABDITIS ELEGANS; COMPUTER MODEL; FUNCTIONAL PROTEOMICS; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN; HUNTINGTON CHOREA; MASS SPECTROMETRY; PHENOTYPE; PROTEIN PROTEIN INTERACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYSTEMS BIOLOGY; TRANSCRIPTOMICS; WILD TYPE; ANIMAL; GENETICS; METABOLISM; METHODOLOGY; REVIEW;

ANIMALS; HUMANS; HUNTINGTON DISEASE; SYSTEMS BIOLOGY;

EID: 80054792149     PISSN: 20412649     EISSN: 20412657     Source Type: Journal    
DOI: 10.1093/bfgp/elr003     Document Type: Article

References (37)

1. Ross CA. Polyglutamine pathogenesis: emergence of unifying mechanisms for Huntington's disease and related disorders. Neuron 2002;35:819-22.
2. Cattaneo E, Zuccato C, Tartari M. Normal huntingtin function: an alternative approach to Huntington's disease. Nat Rev Neurosci 2005;6:919-30.
3. Rubinsztein DC. Functional genomics approaches to neurodegenerative diseases. Mamm Genome 2008;19:587-90.
4. Yang S-H, Cheng P-H, Banta H, etal. Towards a transgenic model of Huntington's disease in a non-human primate. Nature 2008;453:921-4.
5. Raamsdonk J, Hayden M, Leavitt B. Experimental models of Huntington's disease. Drug DiscovToday 2005;2:291-7.
6. Yamamoto A, Lucas JJ, Hen R. Reversal of Neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 2000;101:57-66.
7. Caviston JP, Holzbaur ELF. Huntingtin as an essential integrator of intracellular vesicular trafficking. Trends Cell Biol 2009;19:147-55.
8. Slow EJ, Graham RK, Hayden MR. To be or not to be toxic: aggregations in Huntington and Alzheimer disease. TrendsGenet 2006;22:408-11.
9. Graham RK, Deng Y, Slow EJ, et al. Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell 2006;125: 1179-91.
10. Gonzalez-Couto E, Matteoni S, Gotta S, et al. Huntington's disease: from experimental results to interaction networks, patho-pathway construction and disease hypothesis. BMC Syst Biol 2007;1:P45.
11. Zabel C, Nguyen HP, Hin SC, et al. Proteasome and oxidative phoshorylation changes may explain why aging is a risk factor for neurodegenerative disorders. J Proteomics 2010;73:2230-8.
12. Doran JF, Jackson P, Kynoch PA, et al. Isolation of PGP 9.5, a new human neurone-specific protein detected by high-resolution two-dimensional electrophoresis. J Neurochem 1983;40:1542-7.
13. Picotti P, Bodenmiller B, Mueller LN, et al. Full dynamic range proteome analysis of S. cerevisiae by targeted proteomics. Cell 2009;138:795-806.
14. Kaltenbach LS, Romero E, Becklin RR, et al. Huntingtin interacting proteins are genetic modifiers of neurodegeneration. PLoS Genet 2007;3:e82.
15. Goehler H, Lalowski M, Stelzl U, etal. A protein interaction network links GIT1, an enhancer of huntingtin aggregation, to Huntington's disease. Mol cell 2004;15:853-65.
16. Szklarczyk D, Franceschini A, Kuhn M, etal. The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Res 2010;39(suppl 1):D561-D568.
17. Le Nove're N, Hucka M, Mi H, et al. The systems biology graphical notation. Nat Biotechnol 2009;27:735-41.
18. Li C, Donizelli M, Rodriguez N, et al. BioModels database: an enhanced, curated and annotated resource for published quantitative kinetic models. BMCSyst Biol 2010;4:92.
19. Mi H, Guo N, Kejariwal A, et al. PANTHER version 6: protein sequence and function evolution data with expanded representation of biological pathways. Nucleic Acids Res 2007;35:D247-52.
20. Ganter B, Giroux CN. Emerging applications of network and pathway analysis in drug discovery and development. Curr OpinDrug DiscovDev 2008;11:86-94.
21. Underwood BR, Broadhurst D, Dunn WB, et al. Huntington disease patients and transgenic mice have similar pro-catabolic serum metabolite profiles. Brain 2006;129: 877-86.
22. Heitz F, La Rosa S, Gonzalez-Couto E, et al. Drug discovery and development for Huntington's disease - an orphan indication with high medical need. IDrugs 2008; 11:653-60.
23. Sugars KL, Rubinsztein DC. Transcriptional abnormalities in Huntington disease. Trends Genet 2003;19:233-8.
24. Kita H, Carmichael J, Swartz J, et al. Modulation of polyglutamine-induced cell death by genes identified by expression profiling. HumMol Genet 2002;11:2279-87.
25. Cha J-HJ. Transcriptional signatures in Huntington's disease. Progr Neurobiol 2007;83:228-48.
26. Kuhn A, Goldstein DR, Hodges A, et al. Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. HumMol Genet 2007;16:1845-61.
27. Lein ES, Hawrylycz MJ, Ao N, et al. Genome-wide atlas of gene expression in the adult mouse brain. Nature 2007;445: 168-76.
28. Borovecki F, Lovrecic L, Zhou J, et al. Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease. Proc Natl Acad Sci USA 2005;102: 11023-8.
29. Runne H, Kuhn A, Wild EJ, et al. Analysis of potential transcriptomic biomarkers for Huntington's disease in peripheral blood. ProcNatl Acad SciUSA 2007;104:14424-9.
30. Echeverri CJ, Perrimon N. High-throughput RNAi screening in cultured cells: a user's guide. Nature reviews. Genetics 2006;7:373-84.
31. Hopkins AL, Groom CR. The druggable genome. NatRev Drug Discov 2002;1:727-30.
32. Kitano H. A robustness-based approach to systems-oriented drug design. Nat RevDrug Discov 2007;6:202-10.
33. Doumanis J, Wada K, Kino Y, et al. RNAi screening in Drosophila cells identifies new modifiers of mutant huntingtin aggregation. PloS One 2009;4:e7275.
34. Zhang S, Binari R, Zhou R, et al. A genomewide RNA interference screen for modifiers of aggregates formation by mutant huntingtin in Drosophila. Genetics 2010;184: 1165-79.
35. Nollen EAA, Garcia SM, van Haaften G, et al. Genomewide RNA interference screen identifies previously undescribed regulators of polyglutamine aggregation. Proc Natl Acad SciUSA 2004;101:6403-8.
36. van Ham TJ, Holmberg MA, van der Goot AT, et al. Identification of MOAG-4/SERF as a regulator of age-related proteotoxicity. Cell 2010;142:601-12.
37. van der Burg JM, Björkqvist M, Brundin P. Beyond the brain: widespread pathology in Huntington's disease. Lancet Neurol 2009;8:765-74.